Dr Halliday is a Senior Clinical Lecturer at the National Heart and Lung Institute and a Consultant Cardiologist at Royal Brompton Hospital, Guy's and St Thomas' NHS Trust where he specialises in Cardiomyopathy and CMR. He is also a BHF Intermediate Fellow, having received funding to lead a randomised trial of a mitochondrial targeted antioxidant in patients with dilated cardiomyopathy. He is interested in myocardial recovery and remission and hopes to develop methods that stratify patients with improved cardiac function.
He completed his undergraduate training at University of Edinburgh, before moving to London to continue his clinical training. In 2015, he started a PhD at the NHLI. This included the TRED-HF trial, which set out to examine the safety and feasibility of therapy withdrawal in patients deemed to have recovered dilated cardiomyopathy. He presented the results at the Late Breaking Clinical Trial Sessions at the American Heart Association, 2018 and was primary author of the simultaneous publication in The Lancet.
He also investigated the use of CMR for the risk stratification of patients with dilated cardiomyopathy, focusing on improving the selection of patients for implantable cardioverter defibrillators. He has published articles in several high-impact journals on this topic.
He was awarded his PhD in 2018, along with the NHLI Prize for the Best Thesis. He then continued in the department as a clinical lecturer, focusing on research into dilated cardiomyopathy, myocardial recovery and metabolic dysfunction. During this time he has also developed an interest in 31-phosphorus magnetic resonance spectroscopy through a collaboration with the University of Oxford. He is currently building additional expertise in clinical trials by taking a part-time MSc in Clinical Trials at the Nuffield Department of Public Health, University of Oxford, supported by a grant from the European Society of Cardiology.
et al., 2022, Genetic architecture of acute myocarditis and the overlap with inherited cardiomyopathy, Circulation, ISSN:0009-7322
et al., 2022, The addition of genetic testing and cardiovascular magnetic resonance to routine clinical data for stratification of aetiology in dilated cardiomyopathy, Frontiers in Cardiovascular Medicine, ISSN:2297-055X
Halliday BP, 2022, State of the art: multimodality imaging in dilated cardiomyopathy, Heart, ISSN:1355-6037
et al., 2022, Precision phenotyping of dilated cardiomyopathy using multidimensional data., Journal of the American College of Cardiology, Vol:79, ISSN:0735-1097, Pages:2219-2232
Tayal U, 2022, Exposure to elevated nitrogen dioxide concentrations and cardiac remodelling in patients with dilated cardiomyopathy, Journal of Cardiac Failure, Vol:28, ISSN:1071-9164, Pages:924-934